Clinical responses in the Rituximab and Placebo groups, and response durations for patients with significant responses, derived from self-reported Fatigue scores during 12 months follow-up.

a: p-values from Chi-square statistics.b: One patient was withdrawn from further follow-up registration 28 weeks after inclusion, due to pregnancy. One patient decided to withdraw from the study 42 weeks after inclusion, due to start of alternative therapy. Both patients were allocated to the placebo group and both reported no significant improvement during follow-up. These two were included in the analysis for overall response. Overall response including major and moderate responses, number of patients and proportion (%) with 95% confidence intervals.c: response duration within the 12 months study period, for those achieving a significant response (10 patients in the Rituximab group, and two patients in the Placebo group). In addition, four out of the 10 Rituximab responders had response durations past the formal study period.